Akki, I think we are getting a lot closer to a realistic value...

Akki, I think we are getting a lot closer to a realistic value of PYC at an accelerating rate. If anyone thinks that this company is valued at only 68m, it would be selling it very short. I would offer an alternative positive spin on the previous 12 months with which I believe has been a transformative year based on the announcements alone.

Large holders increasing their holdings !!!!

19 December 2016: Genentech 2.6m Novel Antibiotics (FPPs)
5 December 2016: 750k NHMRC Grant $750k
Blood Cancer Pathways (FPPs)
28 November 2016: Doug Wilson retires, 3 days after AGM
17 November 2016: Tony Barton substantial holder again afer a few years away (1 week before AGM)
15 August 2016: Rohan Hockings non exec alternative director, I wish I knew what that even meant.
18 July 2016: Richard Hopkins resigns (shame I liked him) PYC to become a drug development company ?
1 July 2016: Options expire ( what a bitch)
15 July 2016: PYC & Murdoch Uni (FPPs) improve delivery of drugs into Oligonuotide cells (WOW)
12 April 2016: Bruce McHarrie resigned. Gotta say met him once and he was a true gentleman. Offered me a tour of PYC and I was very greatful
for the offer but time was against me.
18 January 2016: Stephanie Unwin appointed Non Executive Director (corporate lawyer) changing of the guard.

I think that I understand more than most the frustration of PYC but all in all a positive year as at 24 Jan 2016 SP was 0.015 today 0.034.

Mostly large trades recently but the the total volume is a very small percentage of the cap.

Once again I reiterate the science and the lack of value given to the FPPs.

Sell at your peril IMHO as smart money talks and most importantly who else has cell penetrating peptides that can beat the endotrap?

Next question is what is the library worth ?

More than everyone thinks.

All in all a position 12 months ytd